Preserved triamcinolone more likely to cause non-infectious endophthalmitis

Article

Non-infectious endophthalmitis is observed more frequently after injections of triamcinolone acetonide that contain preservatives (PTA) than after injections of preservative-free triamcinolone acetonide (PFTA), according to a study published online ahead of print in the British Journal of Ophthalmology.

Non-infectious endophthalmitis is observed more frequently after injections of triamcinolone acetonide that contain preservatives (PTA) than after injections of preservative-free triamcinolone acetonide (PFTA), according to a study published online ahead of print in the British Journal of Ophthalmology.

Mauricio Maia and colleagues from the Federal University of Sao Paulo, Brazil conducted a retrospective review of 646 intravitreal 4 mg steroid injections in 471 eyes. A total of 577 intravitreal injections of PFTA and 69 injections of PTA were administered in non-randomized eyes. Non-infectious endophthalmitis was defined as pseudohypopyon/hypopyon with or without an inflammatory reaction that regressed after steroid eye drop instillation. Ocular hypertension was defined as more than 23 mmHg with Goldmann applanation tonometry. Subjects were examined one, seven and 28 days post-injection and three, four, six and twelve months after injections.

Ocular hypertension was present in 127 eyes (20%), neither group differing significantly (p=0.167). Four eyes (3.2%) required trabeculectomy. Non-infectious endophthalmitis developed in 12 eyes (1.9%) and varied significantly in both groups (p=0.005); the majority of cases appeared in the PTA group. One eye developed bacterial endophthalmitis (0.15%).

The results revealed that non-infectious endophthalmitis develops more commonly after injections of PTA than after injections of PFTA.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.